Research
Hormonal
Glycemic Variability (GV), defined by a coefficient of variation (CV) >36%, is independently associated with an increased risk of hypoglycemia and diabetes-related complications, regardless of HbA1c levels.
Monitor your Glucose Coefficient of Variation (CV). If your CV is above 36%, your glucose is swinging too much, which increases complication risk. Work with your doctor to smooth out these swings using diet, exercise, or medication adjustments, even if your HbA1c looks okay.
GoodSupportsHIGH confidence
Monnier et al. showed that a percentage coefficient of variation for glucose of 36% appears to be a suitable threshold to distinguish between stable and unstable glycemia in diabetes. It appears that beyond the 36% limit, the frequency of hypoglycemia is significantly increased, especially in insulin-treated subjects.
Why this rating
Based on consensus definitions and multiple studies cited (Monnier, ARIC, etc.).
Source
A View Beyond HbA1c: Role of Continuous Glucose Monitoring
Haleh Chehregosha et al. · Diabetes Therapy · 2019
DOI 10.1007/s13300-019-0619-1
narrative_reviewCited 238×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Continuous Glucose Monitoring (CGM) metrics, specifically Time in Range (TIR) and Glycemic Variability (GV), provide superior clinical insight and safety compared to HbA1c alone by detecting hypoglycemia and glucose excursions that HbA1c misses.Good
- Newer glucose-lowering agents (ultra-long-acting insulin analogs, SGLT2 inhibitors, GLP-1 RAs) reduce Glycemic Variability (GV) and hypoglycemia risk compared to older agents (e.g., insulin glargine 100U/mL) due to smoother pharmacodynamic profiles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →